Skip to main content

ORIGINAL RESEARCH article

Front. Med.
Sec. Ophthalmology
Volume 11 - 2024 | doi: 10.3389/fmed.2024.1494402
This article is part of the Research Topic New Concepts, Advances, and Future Trends in Clinical Research on Eye Diseases View all 3 articles

The safe lowest effective power of subthreshold micropulse laser treatment in Chinese patients with acute or chronic central serous chorioretinopathy

Provisionally accepted
Ting Xie Ting Xie 1,2Wangting Li Wangting Li 2Linli Wang Linli Wang 2Jiafeng Ning Jiafeng Ning 2Zhi Li Zhi Li 2Yulei Chen Yulei Chen 1Xifeng Lin Xifeng Lin 1Shaolin Du Shaolin Du 1*Qingshan Chen Qingshan Chen 2*
  • 1 Dongguan Tungwah Hospital, Dongguan, China
  • 2 Shenzhen Eye Hospital, Shenzhen, China

The final, formatted version of the article will be published soon.

    Purpose: To assess the safe, lowest effective laser power of subthreshold micropulse laser (SML) for treating acute and chronic central serous chorioretinopathy (CSC) in Chinese patients.Methods: Patients were distinguished with acute or chronic CSC based on focal or diffuse retinal pigment epithelium (RPE) leakage on fundus fluorescein angiography (FFA), with or without widespread RPE decompensation. Patients were categorized into five groups and treated with 577 nm yellow SML according to 50% titration power. The change of best-corrected visual acuity (BCVA) and central macular thickness (CMT) were set as primary outcomes. A linear regression model assessed the correlation between different factors and outcome indicators. Result: A total of 103 patients with 127 eyes (61 with acute CSC and 66with chronic CSC) were enrolled. The baseline characteristics were balanced between the five groups (all P > 0.05). The decrease of CMT and the improvement of BCVA were related to the CMT at baseline (all P < 0.05). We found that the lowest effective laser power for acute CSC was 425mw (-225.50 µm vs.

    Keywords: Central serous chorioretinopathy (csc), Subthreshold micropulse laser (SML), Central macular thickness (CMT), Laser power, Treatment

    Received: 10 Sep 2024; Accepted: 18 Oct 2024.

    Copyright: © 2024 Xie, Li, Wang, Ning, Li, Chen, Lin, Du and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Shaolin Du, Dongguan Tungwah Hospital, Dongguan, China
    Qingshan Chen, Shenzhen Eye Hospital, Shenzhen, 518040, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.